Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection (Q33901651)

29 July 2017

title

Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection (English)

1 reference

29 July 2017

main subject

Pseudomonas aeruginosa

0 references

1 reference

Charles S Haworth

1

1 reference

29 July 2017

Juliet E Foweraker

2

1 reference

29 July 2017

Peter Wilkinson

3

1 reference

29 July 2017

Robert F Kenyon

4

1 reference

29 July 2017

Diana Bilton

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

American Journal of Respiratory and Critical Care Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

189

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

975-982

1 reference

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Immunity and bacterial colonisation in bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

British Thoracic Society guideline for non-CF bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Microbiologic follow-up study in adult bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Inflammation: a two-edged sword--the model of bronchiectasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4098097

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

5 July 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

British Thoracic Society national bronchiectasis audit 2010 and 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Quality-of-life determinants in patients with clinically stable bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2208OC

Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition

21 January 2018

1 reference

12 December 2020

Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis

1 reference

12 December 2020

An investigation into causative factors in patients with bronchiectasis

1 reference

12 December 2020

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

12 December 2020

Validation of the St. George's Respiratory Questionnaire in bronchiectasis

1 reference

12 December 2020

10.1164/RCCM.201312-2208OC

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference